Assistant Professor of Pediatrics
Correlating Genomic Features with the Immune Microenvironment in Pediatric Glioma
Glioma is responsible for more childhood deaths and the greatest number of years of potential life lost than any other type of cancer. Despite advances in surgery, radiation and chemotherapy, pediatric supratentorial high grade gliomas (pHGG) including anaplastic astrocytoma and glioblastoma (GBM) are among the most aggressive of these tumors and confer a 2 year survival rate of only ~10-30%. On the contrary, pediatric supratentorial low grade gliomas (pLGG) require less aggressive therapy and are less likely to recur though can be very debilitating with high morbidity. It is imperative that we discover how best to use new therapies for these devastating diseases.
High-grade Gliomas (HGG) or astrocytomas in children nearly always result in a dismal prognosis. Although novel therapeutic approaches are currently in development, preclinical testing has been limited, due to a lack of pediatric-specific HGG preclinical models. These models are needed to help test
Low-Grade Gliomas also called astrocytomas are the most common cancer of the central nervous system in children. They represent a heterogeneous group of tumors that can be discovered anywhere within the brain or spinal cord. Although surgical resection may be curative, up to 20% of children still su